Table 1

Characteristics of patients

FeatureMSONSIONRIONCRIONNMO
n284117199
Age at onset (years) (median (range))33 (23–50)42 (15–71)37 (20–69)45 (29–69)29 (25–69)
Sex (F:M)17:1126:1513:414:56:3
Autoimmune comorbidity (n (%))0/28 (0)4/41 (10)1/17 (6)1/19 (5)1/9 (11)
Serology (where tested) (n (%))
    ANA0/6 (0)2/16 (13)0/4 (0)0/10 (0)1/5 (20)
    RF0/1 (0)0/10 (0)0/4 (0)0/8 (0)0/4 (0)
    Antithyroid antibodiesNot tested0/3 (0)0/4 (0)0/4 (0)0/1 (0)
Treatment (Rx) (n (%))
    Steroids4/28 (14)16/41 (39)16/17 (94)19/19 (100)7/7 (77)
    AZT1/28 (4)5/41 (12)4/17 (24)10/19 (53)3/7 (43)
    PE0/28 (0)1/41 (2)0/17 (0)3/19 (16)1/7 (14)
    Other0/28 (0)5/41 (12)1/17 (6)5/19 (26)3/7 (43)
    Treatment at sampling1/23 (4)11/25 (44)6/8 (75)19/19 (100)9/9 (100)
Follow-up period (months)5 (1–7)30 (12–47)83 (63–175)50 (21–130)67 (37–159)
VA baseline0.1 (0.02–0.25)0.1 (0.01–0.17)0.03 (0–0.08)0.01 (0–0.21)0.01 (0–0.01)
VA follow-up0.67 (0.33–1)0.5 (0.1–0.83)0.21 (0.05–0.67)0.21 (0.003–0.83)0.33 (0.003–0.83)
Relapses of ON2.5 (1–3)0 (0–0)4.5 (3–6.5)4 (2–6)2 (1–6.5)
CSF OCB (n (%))3/4 (75)3/12 (25)0/7 (0)1/11 (9)1/6 (17)
MRI brain MS10 (n (%))20/21 (95)0/26 (0)0/17 (0)0/13 (0)0/7 (0)
MRI spine
    (⩾3 segment myelitis11) (n (%))0/19 (0)0/10 (0)0/6 (0)0/7 (0)5/6 (83)
NMO-IgG (n (%))0/28 (0)2/41 (5)1/17 (6)1/19 (5)5/9 (56)
  • Values are median (interquartile range) or number (%).

  • ANA, antinuclear antibodies; AZT, azathioprine; CRION, chronic relapsing inflammatory optic neuritis; MS, multiple sclerosis; MSON, multiple sclerosis optic neuritis; NMO, neuromyelitis optica; OCB, oligoclonal bands; ON, optic neuritis; PE, plasma exchange; RF, rheumatoid factor; RION, relapsing isolated optic neuritis; SION, single isolated optic neuritis; VA, visual acuity.